These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36579915)

  • 1. Steady-State Pharmacokinetics of Intravenous Hydromorphone in Japanese Patients With Renal Impairment and Cancer Pain.
    Nakatani T; Shiosakai K; Hashimoto T; Shionoya M; Akasaka T; Toyama K; Ishizuka H; Saito Y
    J Palliat Med; 2023 Jun; 26(6):768-775. PubMed ID: 36579915
    [No Abstract]   [Full Text] [Related]  

  • 2. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients.
    Davison SN; Mayo PR
    J Opioid Manag; 2008; 4(6):335-6, 339-44. PubMed ID: 19192761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
    Cass LM; Efthymiopoulos C; Marsh J; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of sparfloxacin in patients with renal impairment.
    Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH
    Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.
    Lobo ED; Heathman M; Kuan HY; Reddy S; O'Brien L; Gonzales C; Skinner M; Knadler MP
    Clin Pharmacokinet; 2010 May; 49(5):311-21. PubMed ID: 20384393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
    Gretler DD; Guerciolini R; Williams PJ
    Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone.
    Collins JJ; Geake J; Grier HE; Houck CS; Thaler HT; Weinstein HJ; Twum-Danso NY; Berde CB
    J Pediatr; 1996 Nov; 129(5):722-8. PubMed ID: 8917240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Safety of Imeglimin in Japanese Patients With Impaired Renal Function.
    Kitamura A; Yumizaki T; Kondo T; Sekino H; Kakuyama H
    J Clin Pharmacol; 2023 Jul; 63(7):807-816. PubMed ID: 36847203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
    Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
    Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
    Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
.
    Min KC; Lasseter KC; Marbury TC; Wrishko RE; Hanley WD; Wolford DG; Udo de Haes J; Reitmann C; Gutstein DE
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):746-752. PubMed ID: 28679468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
    Mallikaarjun S; Forbes WP; Bramer SL
    Clin Pharmacokinet; 1999; 37 Suppl 2():33-40. PubMed ID: 10702885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
    Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
    Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.